Alphatec (NASDAQ:ATEC) Major Shareholder Sells $5,155,000.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Jennifer Pritzker sold 250,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $20.62, for a total value of $5,155,000.00. Following the transaction, the insider directly owned 10,895,045 shares in the company, valued at $224,655,827.90. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Alphatec Trading Up 5.8%

NASDAQ ATEC opened at $21.83 on Wednesday. Alphatec Holdings, Inc. has a 12 month low of $8.69 and a 12 month high of $22.00. The stock has a market capitalization of $3.24 billion, a P/E ratio of -19.32 and a beta of 1.17. The firm’s 50-day moving average is $16.72 and its two-hundred day moving average is $14.32. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to analyst estimates of $182.78 million. The firm’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.28) EPS. Alphatec has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nuveen LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at $135,874,000. Granite Investment Partners LLC lifted its stake in shares of Alphatec by 320.6% in the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock valued at $19,102,000 after purchasing an additional 1,311,748 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Alphatec by 1,818.5% in the first quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock valued at $12,309,000 after buying an additional 1,150,669 shares during the period. Driehaus Capital Management LLC purchased a new stake in Alphatec during the first quarter worth approximately $10,398,000. Finally, Motley Fool Wealth Management LLC purchased a new position in shares of Alphatec in the 1st quarter valued at $9,070,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ATEC. Barclays boosted their target price on Alphatec from $22.00 to $23.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Lake Street Capital set a $25.00 target price on shares of Alphatec and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Morgan Stanley lifted their price objective on Alphatec from $16.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Finally, Stifel Nicolaus assumed coverage on shares of Alphatec in a research report on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.